BioWorld

May 16, 2002

Tranzyme Enters QBI Deal, Targets Neurosensory Drugs

Hyseq, BASF To Finish Deal Early; Hyseq Cutting Employees

Second-Generation LongSAGE' Strategists Say 15,000 Genes In Human Genome Still Uncounted

Nexell's Board OKs Orderly Wind-Down' Of Operations

Other News To Note

Corixa Wants Dispute Resolution For Bexxar Through FDAMA

Corixa Corp. said it is requesting an appeal of the FDA's complete review letter questioning the net clinical benefit and safety of the company's lead cancer product, known as Bexxar. (BioWorld Today) Read More

Today's news in brief

BioWorld

BioWorld briefs for Dec. 17, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for December 17, 2024.

Second insulin receptor offers new therapeutic avenues

BioWorld Science

Investigators at the Helmholtz Institute have shown that inceptor, an inhibitor of the insulin signaling pathway, acted by binding insulin and targeting it for...

Mechanism underlying so-called idiopathic autism inception unveiled

BioWorld Science

Investigators at the Institute for Research in Biomedicine (IRB Barcelona) have unraveled how and why the absence of a neuronal microexon in cytoplasmic...

Drug duo to Repare lack in gyno cancers? Phase I shows promise

BioWorld

Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...